The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2024 | India’s first sequential hematopoietic stem cell and kidney transplant for multiple myeloma
Lalit Kumar, MD, MBBS, All India Institute of Medical Sciences, New Delhi, India, discusses a case study of a 35-year-old woman with multiple myeloma (MM). She was initially treated with bortezomib, dexamethasone, and cyclophosphamide, followed by an autologous stem cell transplant (autoSCT), which improved her myeloma but not her renal function. Subsequently, she underwent a successful kidney transplant and is now doing well. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
